Aktis Oncology, Inc. Common stock (AKTS) is a publicly traded the market company. As of November 12, 2026, AKTS trades at $17.43 with a market cap of $970.56M and a P/E ratio of -9.36. AKTS moved +2.31% today. Year to date, AKTS is +0.00%; over the trailing twelve months it is flat. Its 52-week range spans $13.96 to $34.19. Analyst consensus is strong buy with an average price target of $35.80. Rallies surfaces AKTS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
6 analysts cover AKTS: 0 strong buy, 6 buy, 0 hold, 0 sell, and 0 strong sell. The consensus rating is strong buy. The average price target is $35.80.
| Metric | Value |
|---|---|
| Price | $17.43 |
| Market Cap | $970.56M |
| P/E Ratio | -9.36 |
| EPS | $-1.89 |
| Dividend Yield | 0.00% |
| 52-Week High | $34.19 |
| 52-Week Low | $13.96 |
| Volume | 6 |
| Avg Volume | 0 |
| Revenue (TTM) | $27.38M |
| Net Income | $-167.95M |
| Gross Margin | -2.52% |
6 analysts cover AKTS: 0 strong buy, 6 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $35.80.